Lakefront Biotherapeutics (LKFT) Retained Earnings (2014 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Retained Earnings of -$10.1 million for Q1 2026, down 86.0% year-over-year from -$72.1 million in Q1 2025, and little changed quarter-over-quarter from -$10.1 million in Q4 2025.
Lakefront Biotherapeutics (LKFT) Retained Earnings (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Retained Earnings for 13 consecutive years, with -$10.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 86.0% year-over-year to -$10.1 million; the TTM figure through Mar 2026 stood at -$10.1 million (down 86.0% YoY), while the FY2025 annual figure was -$10.1 million, up 92.99% from the prior year.
- Retained Earnings was little changed at -$10.1 million in Q1 2026 per LKFT's latest filing, from -$10.1 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$5.2 million in Q1 2023 and bottomed at -$506.7 million in Q4 2022.
- Historically, Retained Earnings has averaged -$56.9 million across 5 years, with a median of -$10.1 million in 2025.
- Annual changes were most pronounced in 2023 — Retained Earnings jumped 98.75% — and 2024, when it slumped 2164.67%.
- Lakefront Biotherapeutics' Retained Earnings stood at -$506.7 million in 2022, then surged by 98.75% to -$6.3 million in 2023, then sank by 2164.67% to -$143.5 million in 2024, then soared by 92.99% to -$10.1 million in 2025, then fell by 0.47% to -$10.1 million in 2026.
- Business Quant data shows LKFT's Retained Earnings at -$10.1 million in Q1 2026, -$10.1 million in Q4 2025, and -$10.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Lakefront Biotherapeutics | 1.81 Bn | -1.68 Bn | 1.97 Mn | -10.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.10 Mn |
| Dec 31, 2025 | -10.05 Mn |
| Sep 30, 2025 | -10.86 Mn |
| Jun 30, 2025 | -10.43 Mn |
| Mar 31, 2025 | -5.43 Mn |
| Dec 31, 2024 | -143.52 Mn |
| Sep 30, 2024 | -7.73 Mn |
| Mar 31, 2024 | -6.01 Mn |
| Dec 31, 2023 | -6.34 Mn |
| Sep 30, 2023 | -5.37 Mn |
| Mar 31, 2023 | -5.15 Mn |
| Dec 31, 2022 | -506.75 Mn |
| Mar 31, 2022 | -11.48 Mn |
| Dec 31, 2021 | -420.07 Mn |
| Jun 30, 2021 | -12.97 Mn |
| Dec 31, 2020 | -399.06 Mn |
| Jun 30, 2020 | -5.40 Mn |
| Mar 31, 2020 | -5.43 Mn |
| Dec 31, 2019 | -120.90 Mn |
| Sep 30, 2019 | -817,856.57 |